Sun Pharma issues recall of gout drug due to microbial contamination
2024-03-11
并购微生物疗法
Preview
来源: FiercePharma
Sun Pharma recalled more than 55,000 bottles of the gout treatment febuxostat tablets due to the discovery of microbial contamination at one of its manufacturing facilities.
The U.S. branch of India’s Sun Pharma issued a voluntary recall of more than 55,000 bottles of febuxostat tablets used to treat gout after a report of microbial contamination in the company's manufacturing facility.
The Class II recall, which is what the FDA defines as situations that may cause temporary health consequences or a remote chance of serious health outcomes, was initiated on January 18 and covers 55,272 bottles of 40-milligram and 80-milligram dosages, the agency said in an enforcement report.
Febuxostat is prescribed to reduce uric acid levels in patients diagnosed with gout.
The recalled batches were manufactured at Sun Pharma’s Dadra facility In India for Northstar Rx, which is based in Memphis, and distributed nationwide in the U.S.
The regulatory agency said “microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.”
Sun Pharma was most recently in the news for completing its bid to acquire Taro Pharmaceutical that was initiated 17 years ago. In January, Sun agreed to purchase outstanding shares of Israel-based Taro for $43 each, which equated to a value of $348 million and a 48% premium on Taro’s share price of $29.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。